- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
The epigenetic modifier CC-486 (an oral formulation of azacitidine)1?is a cytidine nucleoside analogue?that is incorporated into newly synthesized DNA as well as RNA.2-4?Once incorporated, CC-486 may deplete DNA methyltransferase 1 (DNMT1), induce DNA damage, and promote hypomethylation of DNA.2,5?The antineoplastic effects of CC-486 are hypothesized to result from this DNA hypomethylation and the ultimate unsilencing of genes involved in cell cycle regulation.2,5
CC-486 Hypothesized Mechanism of Action
CC-486 is an epigenetic modifier hypothesized to induce malignant cell death through the inhibition of protein synthesis or the activation of DNA damage response pathways in hematologic malignancies.
Rationale for Investigation of CC-486 in Hematologic Malignancies